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Abstract
Background: Exercise stress testing (EST) in patients with poor functional capacity measured by time 
on treadmill is typically deemed inconclusive and usually leads to further downstream testing. The aim 
of this study was firstly to evaluate the maximum rate pressure product (MRPP) during initial EST to 
assessthe need for follow-up testing; and secondly to investigate if MRPP is better than age predicted 
maximum heart rate (APMHR) for diagnostic outcome based on follow up cardiovascular (CV) events 
in patients with inconclusive EST due to poor functional capacity. 
Methods: From a total of 2761 tests performed, 236 tests were considered inconclusive due to poor 
functional capacity which were available for analysis. From receiver operating characteristic (ROC) 
analysis, a cut-off value for MRPP of 25000 was chosen using CV events as the outcome measure 
(sensitivity 97%, specificity 45%). Cases were then categorised into those with an MRPP > 25000 and 
< 25000. 
Results: Regardless of treadmill time, any patient attaining an MRPP > 25000 had no abnormal 
downstream testing or CV events at 2 years follow-up. On ROC analysis MRPP outperformed APMHR 
for sensitivity and specificity (area under curve 0.76 vs. 0.59, respectively).  
Conclusions: The results suggest that regardless of functional capacity, individuals whose EST is ter-
minated at maximal fatigue, with no electrocardiogram evidence or symptoms of myocardial ischemia 
and yields an MRPP > 25000, do not require further downstream testing. Furthermore, this group 
of patients, while not immune to future CV events, have significantly better outcomes than those not  
attaining a MRPP > 25000. (Cardiol J 2019; 26, 6: 753–760)
Key words: rate pressure product, exercise stress testing, myocardial ischemia, double 
product, myocardial index
Introduction
Exercise stress testing (EST) in patients with 
poor functional capacity measured solely by time on 
treadmill is typically deemed inconclusive and usu-
ally leads to further investigation such as exercise 
stress echo or dobutamine stress echo, myocardial 
perfusion imaging, computed tomography coronary 
angiography or conventional coronary angiography 
(CA). There is inherent risk involved to the patient 
with some of these tests along with the expense 
of performing such procedures. A more direct as-
754 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 6
sessment of cardiac workload achieved during EST 
would enable better discrimination between  tests 
where cardiac stress was inadequate and those with 
adequate cardiac stress but poor functional capac-
ity. A well validated index of cardiac stress, rate 
pressure product (RPP), although easily available, 
is not routinely used in clinical practice to evaluate 
this important aspect of the test. Normal values 
for RPP have been proposed for clinical and non-
clinical populations at rest and at maximal exercise 
[1–3]. During EST, RPP has been extensively 
investigated as a prognostic variable [4–7]. In a ret-
rospective cohort study of 1759 men, rate pressure 
product reserve (RPPR) (the difference between 
RPP at rest and maximal exercise) was the strong-
est predictor of 7-year cardiovascular (CV) status, 
even after adjustment for age, beta-blocker use and 
Duke Treadmill Score [4]. In the same study, RPPR 
was shown to have greater prognostic power than 
maximum metabolic equivalents (METS), itself 
a key independent predictor of all-cause and CV 
mortality [8, 9]. In addition, RPP has been shown 
to increase the predictive value of EST when 
screening for coronary artery disease (CAD) [6, 7]. 
However, no previous study has used RPP as 
a marker of significant cardiac stress in patients with 
reduced functional capacity and otherwise negative 
EST results. The aim of this study was firstly to 
retrospectively evaluate the MRPP during EST to 
determine the necessity of downstream testing in 
patients with reduced functional capacity (> 15% 
below age and gender predicted functional capacity) 
with an otherwise negative test for myocardial is-
chemia; and secondly assess if MRPP outperforms 
age predicted maximum heart rate (APMHR) for 
diagnostic outcome based on CV events occuring 
during the follow-up period.
Methods
The study sample was drawn from the Logan 
Hospital, a medium-sized public hospital in south-
east Queensland, Australia, and was approved by 
the Metro South Health Service District Human 
Research Ethics Committee, and conforms to the 
declaration of Helsinki. Retrospective data were 
retrieved from all ESTs performed within a 5-year 
window (July 2007 to June 2012). Presentation with 
chest pain suspected to be caused by CAD was the 
main reason for performing EST. All ESTs were 
administered by the same core group of staff on 
a computer-controlled treadmill system (Marquette 
Case; Milwaukee, WI) using the standard Bruce 
protocol [10]. Manual blood pressure measure-
ments were taken by an experienced operator 
at least once every stage, at peak exercise, and 
a minimum of twice during recovery. RPP was cal-
culated by multiplying heart rate (HR) by systolic 
blood pressure (SBP) at each stage and maximal 
rate pressure product (MRPP) was identified. 
Maximum HR and maximum SBP achieved dur-
ing the test were also recorded. Patients received 
a thorough evaluation to assess suitability and to rule 
out clinical evidence of heart failure prior to testing.
The total number of tests performed during 
the collection period was 2761. Any stress test 
deemed negative (2019), positive or equivocal 
(401) (based on electrocardiography changes or 
symptoms of myocardial ischemia), or indetermi-
nate (69) (due to non-cardiorespiratory limitation) 
was excluded from the study, leaving a total of 272 
inconclusive tests. From the 272 tests a further 36 
with known CAD were removed from analysis as 
different clinical management strategies would be 
indicated compared to those without known CAD 
(Fig. 1). The remaining 236 tests were selected 
for analysis based on a functional capacity < 85% 
of age and gender predicted totals performed dur-
ing the initial EST. This chosen cut-off value for 
functional capacity was selected in order to stand-
ardise “poor functional capacity” among our cohort 
and has been previously demonstrated to infer 
a 2-fold absolute risk in CV mortality [9, 11, 12]. 
The decision to perform further testing in this 
group was determined by the treating physician 
based on a patient’s intermediate or moderate pre-
test risk for CAD (minimum of 10% risk in 5 years 
as per Australian Vascular Disease Prevention Alli-
ance) [13] and poor functional capacity. Tests were 
typically performed within 4 weeks from the initial 
test. Mean follow-up was 5 ± 2.4 years (range 2–9 
years) by referencing medical records or through 
contact with the patients’ general practitioner. 
Complete follow-up was possible in all patients 
up to 2 years and potential cost savings of further 
downstream testing generated during this period 
was established. 
A receiver operating characteristic (ROC) 
curve (Fig. 2) was created to establish the MRPP 
cut-point using CV events at mean follow-up 
(5 years) as the outcome. The cut-point chosen 
was the longest vertical deviation from the di-
agonal line and corresponded to a MRPP of 25000 
(sensitivity 97%, specificity 45%, area under curve 
[AUC] 0.76). Two groups were then established for 
analysis: inconclusive EST with MRPP > 25000 
(MRPP > 25), and inconclusive EST with MRPP 
< 25000 (MRPP < 25). ROC analysis was also 
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performed for APMHR (AUC 0.59) based on the 
equation 220 minus age, in order to compare the 
sensitivity and specificity of this commonly used 
measure of sufficient cardiac stress against MRPP. 
Statistical analysis
Quantitative data were summarized as mean 
± standard deviation and t tests for independent 
samples were used to compare variables between 
the two groups. Kaplan-Meier curves were created 
to evaluate all-cause mortality, CV mortality (myo-
cardial infarction, heart failure or undifferentiated 
sudden cardiac death) and CV events (CV mortal-
ity, non fatal myocardial infarction, percutaneous 
coronary intervention [PCI]/balloon angioplasty or 
coronary artery bypass grafting), and the log rank 
test was used to assess statistical significance. Cox 
proportional hazard models were used to establish 
variables significant for all-cause mortality, CV 
mortality and CV events. Catagorical data were 
compared using the Fisher exact test. Data analysis 
was performed using XLSTAT 2017.6 (Addinsoft, 
New York) with a 2-tailed p value < 0.05 considered 
statistically significant.
Results 
Table 1 presents the physical characteristics of 
patients together with their EST measures. There 
was no significant difference in sex distribution 
between the two groups (p = 0.107), however 
the MRPP > 25 group were younger (p < 0.001). 
Resting measures of HR and SBP were significantly 
lower in the MRPP < 25 group (p < 0.001 and 
p = 0.002, respectively). There were significant 
differences in maximum HR, maximum SBP, RPPR, 
APMHR (p < 0.001) treadmill time (p = 0.009) and 
METS (p = 0.003) between the groups. There were 
more patients with obesity in the MRPP > 25 group 
compared to the MRPP < 25 group (p = 0.04). 
Figure 1. Study sampling frame; EST — exercise stress testing; RPP — rate pressure product.
Total EST's available for analysis
N = 2761 (56.6% male)
Age = 51 ± 11.3 years
Excluded 
Excluded 
Included
Positive, equivocal 
or indeterminate 
N = 470 (68.6% male) 
Age = 57 ± 10 years 
Inconclusive EST based on
(< 85% age-predicted functional capacity)
N = 272 (49.2% male)
Age = 53.6 ± 12.6 years
Negative EST 
N = 2019 (56.9% male) 
Age = 49 ± 10.6 years 
 Previous coronary artery disease 
 N = 36 (63.9% male) 
Age = 63.7 ± 9.3 years 
> 25000 RPP
N = 99 (54% male) 
Age = 50.1 ± 10.6 years 
> 25000 RPP
N = 137 (43% male) 
Age = 54.9 ± 11.6 years 
Figure 2. The receiver operating characteristic curve 
for maximum rate pressure product (MRPP) and age-
predicted maximal heart rate (APMHR); 1 — the point 
corresponding to ≥ 85% APMHR; 2 — the longest verti-
cal duration for MRPP; 3 — the longest vertical duration 
for APMHR; AUC — area under curve.
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There were no significant differences between 
the groups with respect to any other measures 
(Table 1). Cox proportional hazard analysis failed to 
demonstrate any significant variable with respect 
to all-cause mortality or CV mortality. Age was the 
only significant predictor for CV events (c2 5.4, p = 
= 0.02, hazard ratio 1.07, 95% CI 1.011–1.132). 
For APMHR, the longest vertical deviation from 
the diagonal on ROC analysis (Fig. 2) corresponded 
to 95% (sensitivity 95%, specificity 25%). At 85% 
APMHR the sensitivity and specificity was 60% 
and 53%, respectively. While a statistical trend 
was noted between assessments of ROC curves 
for MRPP and APMHR, overall this failed to reach 
significance (z = 1.8, p = 0.072; Fig. 2).
All-cause mortality between the two groups is 
shown in Figure 3, with a survival trend towards 
the MRPP > 25 group (p = 0.08). Both CV mortal-
ity and events are also displayed in Figure 2. During 
the 9 year follow-up, 6 patients in the
 MRPP < 25 group passed away due to CV 
cause (5 heart failure, 1 ventricular fibrillation ar-
rest), with no fatalities in the MRPP > 25 group; 
reaching statistical significance at 6 years (p < 0.05). 
The difference in incidence of CV events (MRPP 
> 25 = 3 PCI, MRPP < 25 = 3 balloon angioplasty, 
5 PCI, 4 NSTEMI, 2 STEMI) between the groups 
reached statistical significance (p < 0.05) from 
2 year follow up, with the MRPP > 25 group dis-
playing superior outcomes.
Table 1. Physical characteristics, exercise stress test measures, cardiovascular disease risk factors and 
medications at time of stress test by rate pressure product (RPP) group. 
Maximum RPP > 25000 Maximum RPP < 25000 p
Total 99 137  
Age [years] 50.1 ± 10.6* 54.9 ± 11.6 < 0.001
Male 53 (54%) 59 (43%) 0.1
CVD risk factors 2.3 ± 1.4 2.0 ± 1.3 0.1
Resting HR [bpm] 77 ± 15* 71 ± 13 < 0.001
Resting SBP [mmHg] 130 ± 15* 123 ± 17 0.002
Treadmill time [min:s] 5:32 ± 2:28* 4:42 ± 2:28 0.009
Metabolic equivalents 7.2 ± 2.4* 6.5 ± 2.4 0.003
Maximum SBP [mmHg] 188 ± 21* 155 ± 19 < 0.001
Maximum HR [bpm] 162 ± 19* 130 ± 20 < 0.001
RPPR 20177 ± 4243* 11351 ± 3251 < 0.001
APMHR [%] 95.3 ± 9.4* 78.7 ± 11.4 < 0.001
APMHR < 85% 12 (12.1%)* 96 (70.1%) < 0.001
No risk factors 8 (8.0%) 17 (12.4%) 0.4
Family history 33 (33.3%) 26 (19.0%) 0.06
Diabetes mellitus 30 (30.3%) 24 (17.5%) 0.09
Smoking 32 (32.3%) 59 (43.1%) 0.3
Hypertension 41 (41.4%) 63 (46.0%) 0.7
Dyslipidemia 39 (39.4%) 58 (42.3%) 0.8
Obesity 45 (45.5%)* 36 (26.3%) 0.04
No medications 51 (51.5%) 60 (43.8%) 0.5
Beta-blockers 12 (12.1%) 25 (18.2%) 0.3
Ca2 + blockers 7 (7.0%) 18 (13.1%) 0.2
ACE inhibitors 14 (14.1%) 26 (19.0%) 0.5
ARB’s 13 (13.1%) 13 (9.5%) 0.5
Nitrates 1 (1.0%) 7 (5.1%) 0.1
Statins 26 (26.3%) 50 (36.5%) 0.3
*Significant p < 0.05. Values show number of cases (n), mean ± standard deviation or percentage (%) of the group. ACE — angiotensin convert-
ing enzyme; APMHR — age predicted maximum heart rate; APMHR < 85% — age predicted maximum heart rate less than 85%; ARB — angio-
tensin receptor blocker; CVD — cardiovascular disease; HR — heart rate; RPPR — rate pressure product reserve; SBP — systolic blood pressure
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Table 2 displays the number, type and result 
of downstream testing in both groups performed 
during the initial 2 year follow-up period. A total 
of 81 downstream tests were generated in the 
MRPP > 25 group and 143 in the MRPP < 25 
group. These totals include subsequent testing by 
CA which was performed on all occasions when 
the initial downstream test was positive. None of 
the 17 patients receiving a CA in the MRPP > 25 
group had a positive result, conversely there were 
11 positive tests discovered from 35 CAs performed 
in the MRPP < 25 group (Table 2). Table 3 shows 
the breakdown and costing of further testing in the 
MRPP > 25 group. 
Discussion
The results of the present study suggests 
that in patients with no known CAD, regardless of 
functional capacity (treadmill exercise duration), 
any EST that is terminated at volitional fatigue, 
with no ECG evidence or symptoms of myocardial 
ischemia, and yields an MRPP > 25000 provides 
reassurance that there was no clinically significant 
Figure 3. A. All-cause mortality for rate pressure product groups; B. Cardiovascular mortality for rate pressure product 
groups; C. Cumulative cardiovascular events for rate pressure product groups.
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Table 3. The breakdown of costing from additional testing procedures in the maximum rate pressure 
product > 25 group*. Angiogram figures and computed tomography coronary angiography (CTCA) are 
based on the average cost of tests performed. 
Test Total No. Cost ($AUS) Total cost ($AUS)
Resting echocardiogram 1 230.65 230.65
Dobutamine stress echocardiogram 10 413.80 4130.80
Exercise stress echocardiogram 7 413.80 2896.60
Myocardial perfusion scan 36 834.90 30056.40
CTCA 10 700.00 7000.00
Angiogram 17 855.50 14543.50
All tests  81   58857.95
*MBS Online Medicare Benefits Schedule, Australian Government, Department of Health, viewed 27 July 2016, http://www.health.gov.au/ 
/internet/mbsonline/publishing.nsf/Content/a-z.
Table 2. Results of further testing for maximum rate pressure product (RPP) groups (as defined in text). 
Maximum RPP > 25000 Maximum RPP < 25000
Further testing Total Outcome Angiogram Total Outcome Angiogram
Exercise stress test 0   1 (0)  
Resting echocardiogram 1 (0)   2 (0)  
Dobutamine stress echocardiogram 10 (0) 23 5 (+) 4 (+)
1 re-presented 1 (0) 3 re-presented 3 (0)
Exercise stress echocardiogram 7 (0)   2 (0)  
Myocardial perfusion scan 36 8 (+) 8 (0) 71 12 (+) 2 (+)
10 re-presented 2 (+)
CTCA 10 (0) 1 (0)
Coronary angiogram 5 (0)   11 3 (+)  
DNA 30 3 re-presented 3 (0) 26 2 re-presented 2 (0)
All values show number of cases. (+) indicates positive, (0) indicates negative; CTCA — computed tomography coronary angiography; DNA — 
did not attend follow-up appointment
CAD for up to 2 years follow-up, potentially alle-
viating the need for further downstream testing.
In the current study MRPP outperformed an 
APMHR of ≥ 85% for sensitivity (97% vs. 60%) 
with a nominal difference in specificity (45% vs. 
53%) for the occurrence of CV events during the 
mean follow up (5 years). The sensitivity of 97% 
displayed for MRPP in the current study provides 
great incremental value to an EST performed at 
reduced functional capacity, as very few of these 
patients had CV events during mean follow up 
(5 years). The specificity although modest at 45%, 
is a reflection of the negative downstream testing 
that would otherwise not have been performed in 
the MRPP > 25 group. This could therefore be 
considered extraneous, as clinical advantage has 
already been established due to the high sensitiv-
ity and warranty periods on EST are not clearly 
established [14, 15].
While the difference between the ROC curves 
failed to reach significance (z = 1.8, p = 0.072), 
the AUC for MRPP (0.76) over MHR (0.59) clearly 
demonstrates a superior predictive model. Achiev-
ing 85% of APMHR has been demonstrated to be 
a poor diagnostic and functional endpoint [16]. 
Traditionally, the inability of HR to reach this 
figure has been seen as a marker of chronotropic 
incompetence and a predictor of adverse CV out-
come [17–19]. Many of these studies however 
did not report the corresponding SBP with HR 
and therefore the MRPP was achieved [17, 18]. 
A study by Elhendy et al. [19] although not dis-
cussed in their findings, clearly demonstrated 
a significantly reduced MRPP in the group that 
failed to reach 85% of APMHR. Therefore it may 
be seen that the SBP response to exercise should 
be just as important as the corresponding HR re-
sponse. Bouzas-Mosquera et al. [20] demonstrated 
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that a substantial increase in SBP alone during 
exercise testing was associated with a significantly 
lower risk of mortality and CV events. Individuals 
achieving greater increases in RPP during exercise 
have also been shown to have less CV events over 
time in both those with, and without significant 
CAD [4, 5, 21]. The current study confirms this 
finding, where a significant difference in CV-related 
events was observed between the two groups 
from 2 years follow up (p < 0.05; Fig. 3). A similar 
significant difference between the groups was ob-
served for RPPR (p < 0.01), and although all-cause 
mortality did not reach statistical significance in the 
current study, previous studies have demonstrated 
a similar prognostic advantage when a higher RPPR 
is achieved [4, 5]. Sadrzadeh Rafie et al. [4] showed 
that RPPR possessed a greater prognostic power 
than functional capacity (METS) when compar-
ing individuals with similar functional capacities 
(> 5 METS). Functional capacity (METS) has 
been shown to be an important prognostic meas-
ure for future CV events and mortality [21–23], 
and likewise the current findings demonstrated 
a significant difference between the groups for this 
measure. Allowing that RPP reflects myocardial 
oxygen consumption [24, 25], it would therefore 
seem reasonable that the ability to significantly 
increase RPP in the absence of any substantial 
pathology, be reflective of a normal functioning 
left ventricle. 
Age was the only variable that was statisti-
cally significant (p = 0.02) for the prediction of 
CV events. This in itself would normally predict 
a better prognosis and may have also contributed 
to the older groups (MRPP < 25) poorer treadmill 
time and inability to produce a MRPP > 25000. 
Nevertheless the average age of both groups was 
over 50 years (Table 1) MRPP > 25 = 50.1 ± 10.6 
and MRPP < 25 = 54.9 ± 11.6 and Lloyd-Jones 
et al. [26] demonstrated that having ≥ 2 major CV 
risk factors at the age of 50 years substantially 
increased lifetime CV risk and mortality. In the cur-
rent study, there was no difference between groups 
in regard to the number of CV risk factors (p = 0.1) 
with both groups possessing greater than 2 (Table 1). 
It would therefore be reasonable to accept that 
patients in the current study although exhibiting 
a difference in age, in general still carried a similar 
increased risk for future CV events.
There were no patients in the current study 
achieving a MRPP > 25000 during their EST with 
a positive downstream test during the initial 2 year 
follow-up. Thus, there is potential for significant 
cost savings by avoiding further testing without 
compromising safety. The total number of addi-
tional tests performed in patients with a MRPP 
> 25000 was 81. Of concern are the additional 
8 angiograms that were required when the follow-up 
cardiac stress testing (myocardial perfusion imag-
ing) yielded false positive results. The 81 tests 
would not have been required under the proposed 
model, and would have provided a total cost sav-
ings for the documented facility of approximately 
AUS $59,000 with identical patient outcomes in the 
mean follow-up period (Table 3) [27]. 
While inducible myocardial ischemia typically 
occurs at a similar RPP for an individual [2, 28], 
a set ischemic threshold is not established be-
tween individuals as this can occur at varying RPP, 
depending on the extent of the ischemia, vessels 
involved and compensatory mechanisms present 
[29, 30]. Furthermore, patients that achieve cer-
tain parameters that are interpreted as eliciting 
sufficient cardiac stress, such as > 85% target 
heart rate or > 10 METS, are not necessarily 
immune from significant CAD causing myocar-
dial ischemia [13, 31]. It is for this reason that it 
should be recommended that an MRPP of 25000 
not be used as an arbitrary termination point but 
rather as reassurance once maximal fatigue has 
been reached and the test is otherwise negative 
for myocardial ischemia.
Limitations of the study
The present study is a single center cohort 
study and, therefore, may be subject to selection 
bias. While the outcome data demonstrates sta-
tistical significance for CV events and mortality, 
the AUC for MRPP (0.76) indicates a moderate 
predictive model and further studies with greater 
numbers would be beneficial in order to confirm 
these observations. Although there was no clinical 
evidence of HF prior to EST, echocardiography to 
assess for signs of left ventricular dysfunction prior 
to testing would have been an advantage. Finally, 
the use of MRPP as an index of adequate cardiac 
stress should not replace the clinical decision to use 
downstream testing in those individuals deemed 
to have sufficient risk and high suspicion of CAD.
Conclusions
 The data herein, suggests that in patients 
with an intermediate pre-test risk and no previ-
ous CAD, any EST that is terminated at maximal 
fatigue with patients attaining a MRPP > 25000 
and no electrocardiogram evidence or symptoms 
of myocardial ischemia, do not require further 
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downstream testing. Furthermore, this group of 
patients, while not immune to future CV events, 
have significantly better outcomes than those not 
attaining a MRPP > 25000.  
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